{
  "slug": "magnesium-sleep",
  "file": "magnesium-sleep.review.md (shipped review)",
  "authoring_model": "Sol 6.1",
  "adversarial_reviewer": "Claude Opus 5.5 (Anthropic)",
  "date": "2026-11-02",
  "level_before": "Δ",
  "level_after": "Δ",
  "level_note": "Retained conditionally on M2: if the DRKS00031494 record shows registration after first enrollment (20 April 2023), the adapted SC2 Δ crossing must be re-adjudicated.",
  "confidence_before": "Moderate",
  "confidence_after": "Low",
  "confidence_note": "Proposed, not applied.",
  "pmids_checked": 59,
  "pmids_failed": 0,
  "claims_spot_checked": 14,
  "findings": [
    {
      "id": "M1",
      "severity": "Major",
      "location": "AT A GLANCE table and Belief versus evidence; aggregation paragraph; Final score; scorecard final_score.confidence and confidence_rationale; reader-summary.json implications; web-page.md",
      "original": "The registered clinical subclaim SC2 supports Δ with Moderate confidence. / Multiple independent studies across 59 primary reports with partial replication, but marked methodological heterogeneity in salts, doses, comparators and endpoints remains; evidence density and reproducibility set the band, not reviewer access or correctness.",
      "corrected": "The registered clinical subclaim SC2 supports Δ with Low confidence. / One positive qualifying study unit (PMID 40918053; d=0.2, p=0.049) without independent replication of that endpoint and formulation; the other controlled sleep trials differ in salt, dose, population and endpoint and include primary or global nulls (PMIDs 21199787, 39252819, 37520407). Evidence density and reproducibility set the band at Low, the framework's (Δ, low) pattern.",
      "evidence": "hsef-framework.md Confidence band: Low = small number of studies, little independent replication; example '(Δ, low) - A single causal perturbation supports the mechanism, but independent replication is lacking'. Review tally = 1 positive qualifying unit; web-page.md says trials 'are not interchangeable replications'; 2026-10-14 approval residual says the level is 'one replication away from moving in either direction'. Systematic review PMID 42661485 (2026, 12 RCTs) grades certainty low to very low."
    },
    {
      "id": "M2",
      "severity": "Major",
      "location": "Belief versus evidence; aggregation paragraph; inventory [3]; cap audit; SC2 matrix row and field-valid paragraph; steelman; Final score; Momentum; evidence card [3]; reader-summary.json; web-page.md",
      "original": "A prospectively registered, placebo-controlled bisglycinate trial ... / [3] A prospectively registered four-week bisglycinate trial shows a small primary ISI benefit.",
      "corrected": "A registered (DRKS00031494, registered 'at the time of recruitment' per the report), double-blind, placebo-controlled bisglycinate trial ... / [3] A registered four-week bisglycinate trial (registration timing relative to first enrollment not verified) shows a small primary ISI benefit.",
      "evidence": "PMC12412596 full text and publisher page for PMID 40918053: 'This trial was registered at the German Clinical Trials Register (DRKS) (DRKS00031494) at the time of recruitment'; recruitment March to May 2023, first enrollment 20 April 2023; no registration date and no claim of prospective registration. DRKS page not retrievable (robots-blocked). Load-bearing because the SC2 Δ ladder requires a pre-registered primary outcome; the review flags retrospective registration for the threonate trial but asserts prospective registration here without evidence."
    },
    {
      "id": "m3",
      "severity": "Minor",
      "location": "Final score - Momentum; scorecard extended_scoring_MSD.momentum artifact and justification",
      "original": "the prospectively registered bisglycinate trial DRKS00031494 and the newer threonate trial ACTRN12624000379516 used controlled clinical endpoints, objective wearables and allocation-guess checks",
      "corrected": "the bisglycinate trial DRKS00031494 used a controlled validated symptom endpoint without objective sleep measurement, and the newer threonate trial ACTRN12624000379516 added ring-derived wearables and an allocation-guess check",
      "evidence": "PMID 40918053 full text: questionnaire outcomes only; authors state 'exclusive reliance on self-reported data without objective verification'; no allocation-guess assessment reported."
    },
    {
      "id": "m4",
      "severity": "Minor",
      "location": "review.md lines 46, 48, 227, 229, 267, 317; web-page.md; scorecard causal_tally_audit.items_rejected",
      "original": "Rubric07 ... and06; about1.6points withd=0.2 andp=0.049; Εcould; Γcould; trial37520407; to39252819; bisglycinate4-week; serumMg<0.95mmol/L; the58original ... as58sleep RCTs",
      "corrected": "Rubric 07 ... and 06; about 1.6 points with d=0.2 and p=0.049; Ε could; Γ could; trial 37520407; to 39252819; bisglycinate 4-week; serum Mg <0.95 mmol/L; the 59 original ... as 59 sleep RCTs",
      "evidence": "Known renderer defect. The 2026-10-14 pass recorded A3 (104 replacements) and A5 (the identical web-page.md string) as applied, but these instances remain in the shipped files. No values change."
    },
    {
      "id": "m5",
      "severity": "Minor",
      "location": "Decisive-perturbation inventory tally paragraph; scorecard causal_tally_audit.items_rejected",
      "original": "the 58 original reports must not be marketed as 58 sleep RCTs",
      "corrected": "the 59 original reports must not be marketed as 59 sleep RCTs",
      "evidence": "Banner, REVIEWER NOTES, provenance_header, evidence_inventory (59 entries) and reader-summary all state 59."
    },
    {
      "id": "m6",
      "severity": "Minor",
      "location": "reader-summary.json limitations",
      "original": "59 primary reports with 6 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.",
      "corrected": "59 primary reports, one positive qualifying trial without independent replication, and heterogeneous salts, doses, comparators and endpoints set the confidence; reviewer access depth does not.",
      "evidence": "Lead policy and hsef-framework.md: confidence reflects evidence density and reproducibility. A4 corrected the score card but the public reader summary still prints the access wording."
    },
    {
      "id": "m7",
      "severity": "Minor",
      "location": "REVIEWER NOTES (addition)",
      "original": "(no mention of published syntheses or the oxide-only PCOS null)",
      "corrected": "Add: syntheses as context, not primary credit - 2026 systematic review of 12 stand-alone-magnesium RCTs (PMID 42661485), certainty low to very low, does not support routine insomnia treatment; 2021 meta-analysis of three RCTs in 151 older adults (PMID 33865376), sleep-onset latency -17 min on low to very-low-quality evidence. 10-week magnesium oxide 250 mg vs placebo in PCOS (PMID 36620514): no sleep-quality effect (p=0.85), a population boundary like the postoperative threonate trial.",
      "evidence": "Verified via PubMed metadata: DOIs 10.1080/19390211.2026.2719670 (published 2026-08-28, before cutoff), 10.1186/s12906-021-03297-z, 10.1002/hsr2.1013. 42661485 shares an author (Lopresti) with refs 3 and 19."
    },
    {
      "id": "m8",
      "severity": "Minor",
      "location": "Evidence and causal interpretation; Upper ladder",
      "original": "(Held 2002 cited only as a timeline milestone) / null objective outcomes remain",
      "corrected": "Add: the only placebo-controlled polysomnographic EEG study, a 12-person randomized crossover in healthy older adults (ref 23), reported more slow-wave sleep and higher delta and sigma power; small, not in poor sleepers, unreplicated. / mixed objective outcomes remain (one small positive EEG crossover, null ring-derived outcomes in the newer threonate trial)",
      "evidence": "PMID 12163983 abstract: slow-wave sleep 16.5 vs 10.1 min; delta and sigma power increased (p<=0.05). Favours the hypothesis; does not change the level."
    },
    {
      "id": "E9",
      "severity": "Editorial",
      "location": "Existing 2026-10-14 approval section, rejected finding 4",
      "original": "Six references print the issue year where PubMed carries an e-pub year one apart (refs 5, 7, 10, 15, 19, 41, 56).",
      "corrected": "Nine references ... (refs 5, 7, 10, 15, 19, 26, 41, 42, 56).",
      "evidence": "Sentence says six and lists seven; this pass's metadata comparison finds nine one-year offsets, all within convention. Amend by note."
    },
    {
      "id": "E10",
      "severity": "Editorial",
      "location": "REFERENCES ref 19",
      "original": "(no correction attached)",
      "corrected": "Append: Correction: PMID 42959782 (2026-10-15; published after the literature cutoff; not examined).",
      "evidence": "PubMed Published Erratum to ref 19, DOI 10.3389/fnut.2026.2010644, dated after the 2026-10-12 cutoff. Not a retraction."
    }
  ],
  "rejected_findings": [
    "Tally: 1 positive qualifying unit, 8 printed decisive items ([1],[2],[3],[4],[7],[9],[19],[27]) and 18 discriminating contrasts match the score card evidence_inventory flags.",
    "Aggregation: primary-subclaim rule gives SC2 = Δ; weakest-link Α and scope-matched Δ sensitivities correct.",
    "SC1 lifespan/healthspan and ROS/NAD/senescence quotes come from the declared governing rubric 06-metabolism-aging with an explicit applied adaptation; not template bleed.",
    "Competing-model tournament is substantive (coingredient/expectancy and biomarker-without-benefit rivals at Δ with specific evidence); not a strawman.",
    "Role 'reinforcing / stabilizing factor' follows derivation step 5; M/S/D values do not alter level or confidence.",
    "Bisglycinate responder statement accurate: 26 vs 15 participants with >=6-point ISI reduction, no between-arm test reported.",
    "Glycine 1523 mg correctly described as salt ligand, not an added ingredient.",
    "Adapted SC2 threshold (identical placebo for an ordinary supplement) is declared and reasonable; Δ retained subject to M2.",
    "Falsification patterns flagged 'Additional downgrade: False' correctly not used to lower the level.",
    "No unrelated-hypothesis template bleed found in prose."
  ],
  "lead_policy_applied": {
    "confidence_bands": "Re-derived on evidence density and reproducibility only; access depth excluded. One unreplicated qualifying unit gives Low.",
    "momentum": "Value 'Mechanistic only' correct; artifact wording misattributes design features (m3).",
    "collective_authors": "No blank first author, leading comma or organisation-fragment surname found.",
    "prior_pass": "Earlier corrections A3, A4 (reader summary) and A5 found not fully applied in shipped files (m4, m6)."
  },
  "validator": "Not re-run; recorded PASS - 0 fail, 0 warn, 31 pass",
  "scorecard_changed": false,
  "scorecard_changes_proposed": [
    "final_score.confidence",
    "final_score.confidence_rationale",
    "extended_scoring_MSD.momentum.artifact",
    "extended_scoring_MSD.momentum.justification",
    "causal_tally_audit.items_rejected"
  ],
  "approval": "Not approved as shipped; conditional on M1 and M2 (or documented DRKS verification of prospective registration) and the Minor corrections.",
  "related_files": {
    "prior_adversarial_pass": "ADVERSARIAL REVIEW AND APPROVAL section inside magnesium-sleep.review.md (2026-10-14, findings A1-A5)"
  },
  "residual_limitations": [
    "DRKS registration date not retrievable; M2 is an overclaim finding, not proof of retrospective registration.",
    "Three references read in full text; others at abstract depth.",
    "Diabetic-trial baseline-imbalance statement rests on the earlier pass's Table 6 reading; not re-opened.",
    "Omitted-literature search was targeted, not systematic."
  ]
}